DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cabazitaxel
Cabazitaxel
Re-Visiting Hypersensitivity Reactions to Taxanes: a Comprehensive Review
Jevtana® (Cabazitaxel)
BC Cancer Benefit Drug List September 2021
Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: from Discovery to Implementation
Psma-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer
Jevtana, INN-Cabazitaxel
Chapter 10: Urological Cancer
Human Medicines Highlights Newsletter’ and Then Click on ‘Subscribe to This Feed’
Establishing a Preclinical Multidisciplinary Board for Brain Tumors Birgit V
Jevtana (Cabazitaxel)
Pharmacology Review(S) Memorandum
Cancer Nanobiotechnolgy
Clinical Pharmacology and Biopharmaceutics Review(S)
Chemotherapeutic Drugs in Lebanese Surface Waters: Estimation of Population Exposure and Identifcation of High-Risk Drugs
Provincial Systemic Therapy Program
Cancer Drug Costs for a Month of Treatment at Initial Food
Utility of Prophylactic Antibiotics for Preventing Febrile Neutropenia
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic
Top View
Preclinical Antitumor Activity of Cabazitaxel, a Semi
Bc Cancer Chemotherapy Preparation and Stability
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Prostate Cancer Resistance to Cabazitaxel Chemotherapy
Imbruvica Demonstrates 88% Response Rate in Studies Of
Current Limitations and Recent Progress in Nanomedicine for Clinically Available Photodynamic Therapy
Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer
Emerging Drugs for Prostate Cancer
Separately Chargeable Drugs List
Cabazitaxel Jevtana
Chemotherapy in Patients with Metastatic Prostate Cancer
Jevtana, INN-Cabazitaxel
Mechanisms of Taxane Resistance
EMA/PDCO Summary Report on the Review of the List of Granted Class Waivers
Emetogenic Potential of Antineoplastic Agents
A Treatment Option in Recurrent Platinum-Resistant Ovarian Cancer
Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
Reimbursement Criteria for Frequently Requested Drugs